Business Standard

Thursday, December 19, 2024 | 10:05 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Bharat Biotech rolls out India's first intra-nasal Covid vaccine iNCOVACC

Priced at Rs 800/dose for private players, Rs 325 for bulk procurement by govts

iNCOVACC
Premium

The vaccine’s roll-out is expected to begin in private hospitals that have placed advance orders

Sohini Das Mumbai
Bharat Biotech on Thursday launched the country’s first intra-nasal Covid vaccine iNCOVACC for a primary as well as heterologous (mix-and-match) booster dose in India.

It is the world’s first nasal Covid-19 vaccine that has been approved both as a primary two-dose regimen, and as a heterologous booster after two doses of Covishield or Covaxin.

The vaccine’s roll-out is expected to begin in private hospitals that have placed advance orders.

iNCOVACC is priced at Rs 325 per dose for large volumes procured by states and the Centre. In the private market, the vaccine is priced at Rs 800 per dose.

The

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in